ResMedRMDEarnings & Financial Report
ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.
RMD Q2 2026 Key Financial Metrics
Revenue
$1.4B
Gross Profit
$878.7M
Operating Profit
$491.7M
Net Profit
$392.6M
Gross Margin
61.8%
Operating Margin
34.6%
Net Margin
27.6%
YoY Growth
11.0%
EPS
$2.68
Financial Flow
ResMed Q2 2026 Financial Summary
ResMed reported revenue of $1.4B for Q2 2026, with a net profit of $392.6M (27.6% margin). Cost of goods sold was $544.1M, operating expenses totaled $387.1M.
Key Financial Metrics
| Total Revenue | $1.4B |
|---|---|
| Net Profit | $392.6M |
| Gross Margin | 61.8% |
| Operating Margin | 34.6% |
| Report Period | Q2 2026 |
ResMed Annual Revenue by Year
ResMed annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $5.1B |
| 2024 | $4.7B |
| 2023 | $4.2B |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.20B | $1.22B | $1.22B | $1.28B | $1.29B | $1.35B | $1.34B | $1.42B |
| YoY Growth | 7.2% | 9.0% | 11.1% | 10.3% | 7.9% | 10.2% | 9.1% | 11.0% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.81B | $6.87B | $7.22B | $7.14B | $7.57B | $8.17B | $8.31B | $8.50B |
| Liabilities | $2.18B | $2.01B | $2.03B | $1.89B | $2.02B | $2.21B | $2.19B | $2.18B |
| Equity | $4.63B | $4.86B | $5.20B | $5.25B | $5.55B | $5.97B | $6.12B | $6.32B |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $402.0M | $440.1M | $325.5M | $308.6M | $578.7M | $538.8M | $457.3M | $339.7M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M